Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Human Anti-HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1.

Gawron MA, Duval M, Carbone C, Jaiswal S, Wallace A, Martin JC 3rd, Dauphin A, Brehm MA, Greiner DL, Shultz LD, Luban J, Cavacini LA.

J Immunol. 2019 Feb 1;202(3):799-804. doi: 10.4049/jimmunol.1801085. Epub 2018 Dec 28.

PMID:
30593536
2.

Correction for Giuntini et al., "Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection".

Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD Jr, Barry EM, Cavacini LA, Klempner MS, Wang Y.

Infect Immun. 2018 Nov 20;86(12). pii: e00713-18. doi: 10.1128/IAI.00713-18. Print 2018 Dec. No abstract available.

3.

Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection.

Giuntini S, Stoppato M, Sedic M, Ejemel M, Pondish JR, Wisheart D, Schiller ZA, Thomas WD Jr, Barry EM, Cavacini LA, Klempner MS, Wang Y.

Infect Immun. 2018 Jul 23;86(8). pii: e00355-18. doi: 10.1128/IAI.00355-18. Print 2018 Aug. Erratum in: Infect Immun. 2018 Nov 20;86(12):.

4.

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.

Yu X, Duval M, Gawron M, Posner MR, Cavacini LA.

J Immunol Res. 2016;2016:9425172. doi: 10.1155/2016/9425172. Epub 2016 Jun 22.

5.

Pathogenicity and Epitope Characteristics Do Not Differ in IgG Subclass-Switched Anti-Desmoglein 3 IgG1 and IgG4 Autoantibodies in Pemphigus Vulgaris.

Lo AS, Mao X, Mukherjee EM, Ellebrecht CT, Yu X, Posner MR, Payne AS, Cavacini LA.

PLoS One. 2016 Jun 15;11(6):e0156800. doi: 10.1371/journal.pone.0156800. eCollection 2016.

6.

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.

Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KB, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM.

Science. 2016 Mar 4;351(6277):1078-83. doi: 10.1126/science.aad5788. Epub 2016 Feb 18.

7.

Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients.

Cho MJ, Lo AS, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS.

Nat Commun. 2014 Jun 19;5:4167. doi: 10.1038/ncomms5167.

8.

Development of an HIV-1 Microbicide Based on Caulobacter crescentus: Blocking Infection by High-Density Display of Virus Entry Inhibitors.

Farr C, Nomellini JF, Ailon E, Shanina I, Sangsari S, Cavacini LA, Smit J, Horwitz MS.

PLoS One. 2013 Jun 19;8(6):e65965. doi: 10.1371/journal.pone.0065965. Print 2013.

9.

Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.

Yu X, Duval M, Lewis C, Gawron MA, Wang R, Posner MR, Cavacini LA.

J Immunol. 2013 Jan 1;190(1):205-10. doi: 10.4049/jimmunol.1201469. Epub 2012 Nov 26.

10.

Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus.

Duval M, Lewis CJ, Nomellini JF, Horwitz MS, Smit J, Cavacini LA.

Antimicrob Agents Chemother. 2011 Dec;55(12):5547-52. doi: 10.1128/AAC.00509-11. Epub 2011 Sep 6.

11.

Development of an HIV-1 specific microbicide using Caulobacter crescentus S-layer mediated display of CD4 and MIP1alpha.

Nomellini JF, Li C, Lavallee D, Shanina I, Cavacini LA, Horwitz MS, Smit J.

PLoS One. 2010 Apr 28;5(4):e10366. doi: 10.1371/journal.pone.0010366.

12.

Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Pantophlet R, Wrin T, Cavacini LA, Robinson JE, Burton DR.

Virology. 2008 Nov 25;381(2):251-60. doi: 10.1016/j.virol.2008.08.032. Epub 2008 Sep 26.

14.

Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA.

J Mol Biol. 2008 Jan 25;375(4):969-78. Epub 2007 Nov 13.

15.

The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain.

Miranda LR, Duval M, Doherty H, Seaman MS, Posner MR, Cavacini LA.

J Immunol. 2007 Jun 1;178(11):7132-8.

16.

Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR.

Virology. 2007 Aug 1;364(2):441-53. Epub 2007 Apr 6.

17.

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR.

N Engl J Med. 2006 Oct 26;355(17):1772-9.

18.

Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques.

Ferrantelli F, Buckley KA, Rasmussen RA, Chalmers A, Wang T, Li PL, Williams AL, Hofmann-Lehmann R, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM.

Virology. 2007 Feb 5;358(1):69-78. Epub 2006 Sep 25.

19.

Pathogenic human monoclonal antibody against desmoglein 3.

Yeh SW, Cavacini LA, Bhol KC, Lin MS, Kumar M, Duval M, Posner MR, Ahmed AR.

Clin Immunol. 2006 Jul;120(1):68-75. Epub 2006 Apr 25.

PMID:
16635589
21.
22.

CD40 function in squamous cell cancer of the head and neck.

Cao W, Cavacini LA, Tillman KC, Posner MR.

Oral Oncol. 2005 May;41(5):462-9.

PMID:
15878750
23.

Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.

Cavacini LA, Duval M, Patil A, Wood C, Mayer KH, Ruprecht RM, Posner MR.

J Med Virol. 2005 Jun;76(2):146-52.

PMID:
15834877
24.

Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.

Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR.

Oral Oncol. 2005 Jan;41(1):70-6.

PMID:
15598588
25.

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.

Ferrantelli F, Kitabwalla M, Rasmussen RA, Cao C, Chou TC, Katinger H, Stiegler G, Cavacini LA, Bai Y, Cotropia J, Ugen KE, Ruprecht RM.

J Infect Dis. 2004 Jan 1;189(1):71-4. Epub 2003 Dec 31.

PMID:
14702155
26.

Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals.

Cavacini LA, Kuhrt D, Duval M, Mayer K, Posner MR.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):785-92.

PMID:
14585209
27.

Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.

Kitabwalla M, Ferrantelli F, Wang T, Chalmers A, Katinger H, Stiegler G, Cavacini LA, Chou TC, Ruprecht RM.

AIDS Res Hum Retroviruses. 2003 Feb;19(2):125-31.

PMID:
12639248
28.

Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques.

Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL, Montefiori DC, Cavacini LA, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM.

AIDS. 2003 Feb 14;17(3):301-9.

PMID:
12556683
29.

Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions.

Cavacini LA, Duval M, Robinson J, Posner MR.

AIDS. 2002 Dec 6;16(18):2409-17. Erratum in: AIDS. 2003 Aug 15;17(12):1863.

PMID:
12461414
30.

Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge.

Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Jiang S, Li PL, Baba TW, Montefiori DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Ruprecht RM.

J Med Primatol. 2002 Jun;31(3):109-19.

PMID:
12190851
31.
32.

Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.

Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA, Rasmussen RA, Liska V, Vlasak J, Xu W, Baba TW, Chenine AL, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Montefiori DC, McClure HM.

Transfus Clin Biol. 2001 Aug;8(4):350-8. Review.

PMID:
11642027
33.

Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission?

Hofmann-Lehmann R, Rasmussen RA, Vlasak J, Smith BA, Baba TW, Liska V, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Posner MR, Cavacini LA, Chou TC, Ruprecht RM.

J Med Primatol. 2001 Aug;30(4):190-6.

PMID:
11555137
34.

Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.

Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, Ferrantelli F, Montefiori DC, McClure HM, Anderson DC, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Katinger H, Stiegler G, Cavacini LA, Posner MR, Chou TC, Andersen J, Ruprecht RM.

J Virol. 2001 Aug;75(16):7470-80.

35.

Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.

Xu W, Smith-Franklin BA, Li PL, Wood C, He J, Du Q, Bhat GJ, Kankasa C, Katinger H, Cavacini LA, Posner MR, Burton DR, Chou TC, Ruprecht RM.

J Hum Virol. 2001 Mar-Apr;4(2):55-61.

PMID:
11437315
36.

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, Cavacini LA, Posner MR, Katinger H, Stiegler G, Bernacky BJ, Rizvi TA, Schmidt R, Hill LR, Keeling ME, Lu Y, Wright JE, Chou TC, Ruprecht RM.

Nat Med. 2000 Feb;6(2):200-6.

PMID:
10655110
37.

A human anti-HIV autoantibody enhances EBV transformation and HIV infection.

Cavacini LA, Wisnewski A, Peterson JE, Montefiori D, Emes C, Duval M, Kingsbury G, Wang A, Scadden D, Posner MR.

Clin Immunol. 1999 Dec;93(3):263-73.

PMID:
10600338
38.

Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

Cavacini LA, Peterson JE, Nappi E, Duval M, Goldstein R, Mayer K, Posner MR.

J Virol. 1999 Nov;73(11):9638-41.

39.
40.

The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck.

Posner MR, Johnston PG, Tishler RB, Andersen J, Fiorentino M, Busse PM, Cavacini LA, Colevas AD, Clark J, Norris CM.

Oncologist. 1998;3(6):424-431.

41.

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.

Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, Posner MR.

AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1271-80.

PMID:
9764911
42.

Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120.

Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, Hammer S, Koziel C, Trapnell C, Posner MR.

AIDS Res Hum Retroviruses. 1998 May 1;14(7):545-50.

PMID:
9591708
43.

Pharmacokinetics of F105, a human monoclonal antibody, in persons infected with human immunodeficiency virus type 1.

Wolfe EJ, Cavacini LA, Samore MH, Posner MR, Kozial C, Spino C, Trapnell CB, Ketter N, Hammer S, Gambertoglio JG.

Clin Pharmacol Ther. 1996 Jun;59(6):662-7.

PMID:
8681491
44.

Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.

Cavacini LA, Emes CL, Power J, Desharnais FD, Duval M, Montefiori D, Posner MR.

J Immunol. 1995 Oct 1;155(7):3638-44.

PMID:
7561063
45.

Plasma pharmacokinetics and biological activity of a human immunodeficiency virus type 1 neutralizing human monoclonal antibody, F105, in cynomolgus monkeys.

Cavacini LA, Power J, Emes CL, Mace K, Treacy G, Posner MR.

J Immunother Emphasis Tumor Immunol. 1994 May;15(4):251-6.

PMID:
8061897
46.

Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.

Cavacini LA, Emes CL, Power J, Duval M, Posner MR.

J Immunol. 1994 Mar 1;152(5):2538-45.

PMID:
7510748
47.

Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression.

Cavacini LA, Emes CL, Power J, Underdahl J, Goldstein R, Mayer K, Posner MR.

J Acquir Immune Defic Syndr. 1993 Oct;6(10):1093-102.

PMID:
7692037
49.
50.

Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120.

Posner MR, Cavacini LA, Emes CL, Power J, Byrn R.

J Acquir Immune Defic Syndr. 1993 Jan;6(1):7-14.

PMID:
8417177

Supplemental Content

Loading ...
Support Center